Myopia Profile

Have you seen our updated Myopia Management Guidelines Infographics? Hugely popular, first launched in 2019 and now with a new look in various print formats and 11 languages! We've released a series of articles on Myopia Profile to help you put the Infographics into practice. The best place to start is by reading the article below, and we'll go through the series this week. USING THE MANAGING MYOPIA GUIDELINES INFOGRAPHICS The infographic contains two components differentiated by their color schemes. --> The mostly blue infographic is a chairside reference guide for eye care professionals which guides you through: (1) Myopia risk factors, (2) What to prescribe, (3) Follow-up schedules and (4) Gauging success --> The multi-colored infographic is designed to help you communicate with parents and patients on the following topics: (1) Visual environment advice, (2) What are my options? (3) Kids can wear contact lenses and (4) Why myopia management is essential. Learn how to use the Infographics, and the matching take-home brochure, in this summary article. https://lnkd.in/gAD4YP7g #myopia #myopiacontrol #myopiamanagement #professionallearning

#ARVO2024 Update 32: Microsaccade Characteristics through-focus when using Multifocal Contact Lenses in Myopes and Emmetropes as a function of the target frequency content. Maher Khushashi and colleagues from the University of Detroit Mercy, USA. In this study, binocular microsaccades were measured with correction of refractive error in an optical system which did not induce any lens magnification or minification. Participants were measured under three conditions: naked eye (refractive error corrected), with Biofinity +1.50D and +2.50D multifocal soft contact lenses. Emmetropes make larger (potentially more accurate) microsaccades in the presence of induced blur, compared to myopes, who take more microsaccades, and even more again when wearing multifocal soft contact lenses. Microsaccades serve to bring the fovea back to fixation - the impact of more saccades on ocular or mental fatigue is not fully known. Abstract link: https://lnkd.in/g2yh_Naz Image: a streetscape sculpture in Seattle.

#ARVO2024 Update 31: Longitudinal evaluation of accommodation in children at low and high risk for developing myopia. Kristen Kerber (left) and colleagues from New England College of Optometry, Boston USA, including Fuensanta A. Vera-Diaz (at right). Since inaccurate accommodative responses (ARs) to blur may be associated with myopia development, this study measured static and dynamic AR's in young children (mean age 7.5 yrs) every 6 months for 24 months. They were classified as low risk or high risk for myopia based on parental myopia and baseline refraction. All children were emmetropic to start with, with those at low risk and high risk of myopia showing greater static accommodative lags after 18 months. Those at high risk had reduced accuracy of ARs (greater lags) throughout the 24 months, and the difference in both static and dynamic measures increased under binocular conditions. This indicates that differences in AR in young children could be helpful in predicting myopia development. Abstract link: https://lnkd.in/g7TDxFbz

#ARVO2024 Update 30: Randomized controlled trial of eye movement exercise based digital therapeutics for inhibiting myopia progression. Byung Joo Lee and co-authors from University of Ulsan College of Medicine, Korea, including Youngmin Huh, pictured. The authors randomized 60 children (5-12 years) into two groups - the control group wearing spectacles only, and the SAT-001 group where spectacle wearers engage in a program with guided eye movement exercises: including 'eye movement games, relaxation sessions and promotion of a well-lit environment'. At 48 weeks, the SAT-001 showed a small, insignificant reduction in myopic progression (SER change -0.62 D in OS, -0.53 D in OD) compared to the control group (SER change -0.85 D in OS, -0.84 D in OD). When stratified according to age, the younger SAT-001 group showed significantly less myopia progression (SER change -0.61 D in OS, -0.50 D in OD) compared to controls (mean SER change -1.18 D in OS, -1.22 D in OD). Axial elongation was also smaller in the intervention group (0.38 mm) compared to controls (0.59 mm). Abstract link: https://lnkd.in/gwa8uZHW #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 29: Regional differences in optical coherence tomography (OCT) optic nerve head and macula parameters for detecting glaucoma in eyes with and without high axial myopia. Jasmin Rezapour and co-authors from Ophthalmology, Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Germany. Glaucoma in high myopes can be difficult to diagnose due to the myopic optic nerve changes that have occured. The authors compared glaucomatous to healthy eyes, dividing the groups into no myopia, mild myopia (24-26mm axial length) and high myopia (axial length >26mm). They found that diagnostic accuracy for high myopes was higher using global and infero-temporal peripapillary retinal nerve fibre layer (RNFL) metrics whilst for non-myopes and low myopes it was using Bruch’s membrane opening minimum rim width. Sectoral macular ganglion cell inner plexiform layer was also more accurate than macular RNFL thickness for high myopes. Abstract link: https://lnkd.in/gf5cCX3g Image: another super busy poster session at ARVO. #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 28: Defocus Incorporated Multiple Segment lenses and 0.025% atropine for myopia control in a European population: 12-month results of a randomized clinical trial. Noemi Guemes-Villahoz from Hospital Clinico San Carlos, Spain, and co-authors. This randomized controlled trial compared the efficacy of combination treatments 0.025% atropine and DIMS lenses with 0.025% atropine and single vision (SV) lenses in slowing myopia progression in European myopic children (n=56) aged 4-16 years over 12 months. Combination treatment with 0.025% atropine and DIMS lenses were more effective than 0.025% atropine and SV lenses in controlling axial elongation, with only 0.07mm growth over 12 months in the combo group compared to 0.20mm in the (slightly younger) atropine group. Definitive data on whether adding 0.05% atropine boosts DIMS efficacy would require comparison to a DIMS monotherapy group, but the small absolute growth indicates a possible synergistic effect. Abstract link: https://lnkd.in/gnxPWKmd Pictured: a busy exhibitor session in the Exhibition Hall, image by ARVO. #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 27: Myopia optical treatments within a UK clinic population are less successful than in clinical trials. Mhairi Day and co-authors from Department of Vision Sciences, Glasgow Caledonian University, Glasgow, UK. This study sought to expand on previous findings that showed 30% of patients received successful myopia management treatment in a UK clinic setting. Clinical record data was extracted for a total 40 patients across a range of treatment methods: DIMS lens, multifocal, Ortho-K and dual focus. Treatment efficacy evaluation was made based on axial length data using three efficacy criteria: mean efficacy reported in clinical trials; emmetropic eye growth rate and 'responder' classification by growth of less than 0.11mm/year. The axial length growth rate before treatment of 0.28mm/year compared well to control groups, and was reduced to 0.17mm/year (mean reduction 0.12mm/year) with treatment. By these efficacy criteria, average 'success' rates for the treatments were between 22 and 46%, and the rate of ‘non-responders’ with axial progression of ≥0.11mm/yr was 68%. Larger scale data, evaluating these criteria by age and other factors, would help to illuminate any differences between observed and reported success rates of myopia control treatments. Abstract link: https://lnkd.in/gd3bJWvf Image: We didn't get the chance to meet this author in person, and here's why - check out the monstrously popular and busy state of this poster session! #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 26: The short-term effects of spectacle-based myopia management interventions on dynamic vision. Leon Davies from Aston University, UK and colleagues from Aston and SightGlass Vision. Twenty adults age 18-30 wore spherical soft contact lenses to correct their low to moderate myopia, and sequentially wore plano myopia control spectacle lenses with Diffusion Optics Technology (DOT), Defocus Incorporated Multiple Segments (DIMS), Highly Aspherical Lenslets (HAL), and single vision (SV). Hart Chart dynamic vision test showed no differences and no impact of the myopia control designs. All myopia control lens designs performed similarly and no different to single vision for Hart Chart dynamic vision test and Circles Search test through lens centre and lens periphery. Peripheral near acuity threshold and critical print size were affected by DIMS, but HAL and DOT were similar to SV. This data in adults shows dynamic vision performs well across myopia control lens types, with a potential difference between lens types in reading performance. Abstract link: https://lnkd.in/gPcnmgjb #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 25: Highly Aspherical Lenslet Target (HALT) technology in combination with low-dose atropine to control myopia progression. Aldo Vagge (left) from the University Eye Clinic of Genoa, Italy, and co-authors; pictured with Kate Gifford of Myopia Profile (centre) and Prof. Dr. Hakan Kaymak from Germany (at right), who was amongst the first to publish on myopia control spectacles in combination with atropine. This retrospective study evaluated the efficacy of HALT lenses combined with 0.01% atropine eye drops in slowing myopia progression amongst myopic children aged 6-13 years (n=175). Compared to HALT or 0.01% atropine monotherapy, combination treatment showed significantly less myopia progression (D) over 12 months. A significant difference for axial length was only found between combination treatment and atropine groups, but not between combination and HALT. This indicates that HALT and the combination slow axial growth more than 0.01% atropine, but more data would be required to determine an additive effect of the combination for millimetre control as well as dioptre control. Abstract link: https://lnkd.in/gfqZgDG9 #myopia #myopiacontrol #myopiamanagement #professionallearning #research

#ARVO2024 Update 24: Myopia control effect of Defocus Incorporated Multiple Segments lenses in an Indian population with progressive myopia. Shruti.D. Nishanth and co-authors from Maastricht Universitair Medisch Centrum, Netherlands and Chennai, India (second from right), pictured with Kate Gifford and Paul Gifford of Myopia Profile, and Chi-ho To from Hong Kong Polytechnic (at right), an author on the original DIMS efficacy study. This prospective, non-randomized study evaluated myopia progression in 50 children aged 7-17yrs and upon identification as a progressor (at least 0.50D in 6 months), they were fit with Defocus Incorporated Multiple Segments (DIMS) spectacle lenses, or continued with single vision (self-selected). After 12mths wear, the control group of 25 age-matched children had progressed -0.75D and 0.3mm. In the DIMS group, 32% of eyes had no refractive progression and 42% of eyes had axial length change of less than 0.1mm, indicating myopia stability. This is the first such data on DIMS efficacy in children of South Asian ethnicity, with results appearing to be in line with those found in the original Hong Kong study. Abstract link: https://lnkd.in/g7XZZ-p4 #myopia #myopiacontrol #myopiamanagement #professionallearning #research